Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367
Met Ö, Jensen KM, Chamberlain CA et al (2019) Principles of adoptive T cell therapy in cancer. Semin Immunopathol 41:49–58. https://doi.org/10.1007/s00281-018-0703-z
Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480–1492. https://doi.org/10.1016/S1470-2045(18)30700-9
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–723. https://doi.org/10.1016/j.cell.2017.01.017
Draghi A, Chamberlain CA, Furness A, Donia M (2019) Acquired resistance to cancer immunotherapy. Semin Immunopathol 41:31–40. https://doi.org/10.1007/s00281-018-0692-y
Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37:443–455. https://doi.org/10.1016/j.ccell.2020.03.017
Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25–39. https://doi.org/10.1038/s41577-019-0218-4
Peggs KS, Quezada SA, Allison JP (2008) Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224:141–165. https://doi.org/10.1111/j.1600-065X.2008.00649.x
Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197–218. https://doi.org/10.1038/s41573-018-0007-y
Capone E, Iacobelli S, Sala G (2021) Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. J Transl Med 19:405. https://doi.org/10.1186/s12967-021-03085-w
Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44. https://doi.org/10.1016/j.cell.2016.02.065
Gokuldass A, Schina A, Lauss M et al (2021) Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03015-1
De Ponte Conti B, Miluzio A, Grassi F, et al (2021) mTOR-dependent translation drives tumor infiltrating CD8+ effector and CD4+ Treg cells expansion. Elife 10. https://doi.org/10.7554/eLife.69015
Martinez-Val A, Guzmán UH, Olsen JV (2022) Obtaining complete human proteomes. Annu Rev Genomics Hum Genet 23. https://doi.org/10.1146/annurev-genom-112921-024948
Alberts B, Bray D, Hopkin K, et al (2015) Essential cell biology, 4th ed. Garland Science, London, England
Tanaka K, Waki H, Ido Y et al (1988) Protein and polymer analyses up tom/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2:151–153. https://doi.org/10.1002/rcm.1290020802
Qin W, Cho KF, Cavanagh PE, Ting AY (2021) Deciphering molecular interactions by proximity labeling. Nat Methods 18:133–143. https://doi.org/10.1038/s41592-020-01010-5
Christopher JA, Stadler C, Martin CE, et al (2021) Subcellular proteomics. Nat Rev Methods Primers 1. https://doi.org/10.1038/s43586-021-00029-y
Riley NM, Coon JJ (2016) Phosphoproteomics in the age of rapid and deep proteome profiling. Anal Chem 88:74–94. https://doi.org/10.1021/acs.analchem.5b04123
Akimov V, Barrio-Hernandez I, Hansen SVF et al (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25:631–640. https://doi.org/10.1038/s41594-018-0084-y
Hansen BK, Gupta R, Baldus L et al (2019) Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation. Nat Commun 10:1055. https://doi.org/10.1038/s41467-019-09024-0
Fenn JB, Mann M, Meng CK et al (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64–71. https://doi.org/10.1126/science.2675315
Purvine S, Eppel J-T, Yi EC, Goodlett DR (2003) Shotgun collision-induced dissociation of peptides using a time of flight mass analyzer. Proteomics 3:847–850. https://doi.org/10.1002/pmic.200300362
Eng JK, McCormack AL, Yates JR (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5:976–989. https://doi.org/10.1016/1044-0305(94)80016-2
Beck L, Harel M, Yu S et al (2021) Clinical proteomics of metastatic melanoma reveals profiles of organ specificity and treatment resistance. Clin Cancer Res 27:2074–2086. https://doi.org/10.1158/1078-0432.CCR-20-3752
Buczak K, Kirkpatrick JM, Truckenmueller F et al (2020) Spatially resolved analysis of FFPE tissue proteomes by quantitative mass spectrometry. Nat Protoc 15:2956–2979. https://doi.org/10.1038/s41596-020-0356-y
Aran D, Hu Z, Butte AJ (2017) xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:1–14. https://doi.org/10.1186/s13059-017-1349-1
Satpathy S, Krug K, Jean Beltran PM et al (2021) A proteogenomic portrait of lung squamous cell carcinoma. Cell 184:4348-4371.e40. https://doi.org/10.1016/j.cell.2021.07.016
Lehtiö J, Arslan T, Siavelis I et al (2021) Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nat Cancer 2:1224–1242. https://doi.org/10.1038/s43018-021-00259-9
Myers SA, Rhoads A, Cocco AR et al (2019) Streamlined protocol for deep proteomic profiling of FAC-sorted cells and its application to freshly isolated murine immune cells. Mol Cell Proteomics 18:995–1009. https://doi.org/10.1074/mcp.RA118.001259
Amon S, Meier-Abt F, Gillet LC et al (2019) Sensitive quantitative proteomics of human hematopoietic stem and progenitor cells by data-independent acquisition mass spectrometry. Mol Cell Proteomics 18:1454–1467. https://doi.org/10.1074/mcp.TIR119.001431
Tsai S, McOlash L, Palen K, et al (2018) Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 18. https://doi.org/10.1186/s12885-018-4238-4
Andersen R, Borch TH, Draghi A et al (2018) T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Ann Oncol 29:1575–1581. https://doi.org/10.1093/annonc/mdy139
Tanzer MC, Bludau I, Stafford CA et al (2021) Phosphoproteome profiling uncovers a key role for CDKs in TNF signaling. Nat Commun 12:6053. https://doi.org/10.1038/s41467-021-26289-6
Bartok O, Pataskar A, Nagel R et al (2021) Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590:332–337. https://doi.org/10.1038/s41586-020-03054-1
Pataskar A, Champagne J, Nagel R et al (2022) Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature. https://doi.org/10.1038/s41586-022-04499-2
Celis-Gutierrez J, Blattmann P, Zhai Y et al (2019) Quantitative interactomics in primary T cells provides a rationale for concomitant PD-1 and BTLA coinhibitor blockade in cancer immunotherapy. Cell Rep 27:3315-3330.e7. https://doi.org/10.1016/j.celrep.2019.05.041
Boucherit N, Gorvel L, Olive D (2020) 3D tumor models and their use for the testing of immunotherapies. Front Immunol 11:603640. https://doi.org/10.3389/fimmu.2020.603640
Chong C, Coukos G, Bassani-Sternberg M (2022) Identification of tumor antigens with immunopeptidomics. Nat Biotechnol 40:175–188. https://doi.org/10.1038/s41587-021-01038-8
Zhao Q, Laverdure J-P, Lanoix J, et al (2020) Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer. Cancer Immunology Research canimm.0541.2019. https://doi.org/10.1158/2326-6066.cir-19-0541
Tran E, Robbins PF, Rosenberg SA (2017) “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18:255–262. https://doi.org/10.1038/ni.3682
Bassani-Sternberg M, Bräunlein E, Klar R et al (2016) Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 7:13404. https://doi.org/10.1038/ncomms13404
Chong C, Müller M, Pak H et al (2020) Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat Commun 11:1293. https://doi.org/10.1038/s41467-020-14968-9
Sarkizova S, Klaeger S, Le PM et al (2020) A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38:199–209. https://doi.org/10.1038/s41587-019-0322-9
Anderson NL (2010) The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56:177–185. https://doi.org/10.1373/clinchem.2009.126706
Barichello T, Generoso JS, Singer M, Dal-Pizzol F (2022) Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review. Crit Care 26:14. https://doi.org/10.1186/s13054-021-03862-5
Lauwyck J, Beckwée A, Santens A et al (2021) C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Res 31:371–377. https://doi.org/10.1097/CMR.0000000000000748
留言 (0)